Metaplanet invests in therapeutic delivery platform developer Granza Bio
Jaan Tallinn's fund Metaplanet has invested in California-based therapeutic delivery platform developer Granza Bio. The $7.14M seed round was led by California-based VCs Felicis and Refactor, with participation from US accelerator Y Combinator, Zeno Ventures, the US Ritual Capital, Pioneer Fund, Oxford Angel Fund, North-South Ventures, and some business angels.
Founded in 2024 by Ashwin Menon Nandakumar, Ashwin Jainarayanan, and Michael Dustin, Professor of Molecular Immunology at the University of Oxford, Granza Bio develops a delivery platform to target therapeutic cargo to different parts of the body and target it against diseases, for instance, cancer, autoimmune disorders, and infections. The therapeutic cargo aims to kill cancer cells leaving healthy cells untouched, thus avoiding any unwanted toxicity or side effects.
The startup will use the investment to expand the biotech’s research beyond the initial experimentation phase and to develop further.
Metaplanet Holdings is Jaan Tallinn's (Skype’s founder) early-stage investment firm. The fund has more than 160 companies in its venture investment portfolio.